Abstract
Prostate cancer is the most common noncutaneous cancer among men. This case report describes a 43-year-old man with rapidly progressing castration-resistant prostate cancer (CRPC) that responded initially to docetaxel and did not tolerate cabazitaxel. He subsequently received a third line of chemotherapy with cyclo-phosphamide and prednisone, and experienced a dramatic clinical and radiographic response in his liver metastases. This therapeutic intervention led to a significant clinical benefit and confirms the potential use of cyclophosphamide in patients with CRPC, particularly those with liver metastases.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 911-915 |
| Number of pages | 5 |
| Journal | JNCCN Journal of the National Comprehensive Cancer Network |
| Volume | 11 |
| Issue number | 8 |
| State | Published - Aug 1 2013 |
| Externally published | Yes |
ASJC Scopus subject areas
- Oncology